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A Case of Ipilimumab Induced Hypophysitis
Eric Shiffrin, MD and Melinda Ukrainski, MD

Figure 1. Postcontrast T1-weighted magnetic resonance image
of the brain two days prior to the fourth dose of ipilimumab and
hospital admission, demonstrating diffuse enlargement of the
pituitary gland (arrow).

Introduction
Ipilimumab (Yervoy®) is a human monoclonal antibody
that has been shown to significantly improve survival
in cases of metastatic melanoma.1 Ipilimumab blocks
cytotoxic T-lymphocyte antigen 4 (CTLA-4), a protein
receptor on the surface of T-cells, resulting in their
activation, proliferation and an anti-tumor response.2,3,4
Commonly reported immune-related side effects of
ipilimumab are enterocolitis, dermatitis, and hepatitis.5,6,7
However, different endocrinopathies, including
autoimmune hypopituitarism, have become emerging
clinical entities in patients taking ipilimumab. We present
a case of ipilimumab induced hypophysitis in a 62-yearold male presenting with fatigue and hypotension.

Case Presentation
A 62-year-old male with a history of melanoma metastatic
to the lung and brain status-post frontal craniotomy and
whole brain radiation, as well as a recent diagnosis of
hypothyroidism, presented from the oncology office with
hypotension after receiving his fourth dose of ipilimumab
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Figure 2. Postcontrast T1-weighted magnetic resonance image of
the brain three months before presentation and prior to starting
ipilimumab, demonstrating normal pituitary gland architecture
and size (arrow).

therapy. The patient had a routine blood pressure check
after the chemotherapy infusion and was found to be
hypotensive at 80/58 mmHg. He reported increasing
fatigue over the past week. He denied chest pain,
shortness of breath, dizziness and headache. He was
given one liter of normal saline solution, but remained
hypotensive and was directly admitted to the hospital.
On physical exam, the patient was tachycardic to 102
beats per minute with a regular rhythm, clear lungs, and
positive orthostatics. Laboratory studies were significant
for a thyroid stimulating hormone of <0.02 uIU/mL
(normal range = 0.3 – 5 uIU/mL), free T4 of 1.2 ng/dL
(normal range = 0.7 – 1.7 ng/dL), follicle stimulating
hormone of 0.9 mIU/mL (normal range 1.5 – 12.4 mIU/mL),
adrenocorticotropic hormone (ACTH) of <9 pg/mL (normal
range 9 – 46 pg/mL), total testosterone of 4 ng/dL (normal
range 250 – 1100 ng/dL, and a free testosterone of
0.4 pg/mL (normal range 35 – 155 pg/mL). His white blood
cell count, hemoglobin and electrolytes were within
normal limits. A noon cortisol was 0.3 mcg/dL (normal
A.M. range 16 – 20 mcg/dL and P.M. range 2 – 12 mcg/dL)
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and a subsequent cosyntropin stimulation test with 250 µg
of cosyntropin resulted in cortisol values of 5.4 mcg/dL
and 8.8 mcg/dL at one hour and two hours respectively.
An a magnetic resonance image (MRI) of the brain with
and without contrast performed two days earlier for
surveillance of his known brain metastases was reviewed
on admission and revealed diffuse enlargement of the
pituitary gland (Figure 1). This finding was new compared
to an MRI performed three months earlier, prior to
starting ipilimumab (Figure 2). The patient had no family
history of endocrine disorders.

Discussion
Endocrine-related adverse events were reported in 8.5%
of patients in a recent phase III trial designed to evaluate
ipilimumab as an adjuvant therapy following resected
stage III melanoma, with hypophysitis encompassing
5.1% of these events.8 The majority of patients who
develop hypopituitarism do so after the third or fourth
dose of ipilimumab, suggesting a possible cumulative
effect.1,3 Adverse events have limited the duration of
use of the drug in patients who could have clinical
benefit from additional therapy.
The mechanism of hypopituitarism is likely from
ipilimumab’s immunomodulatory effect on activating
T-cells, resulting in a lymphocytic hypophysitis.2,3,5,6 It
has also been shown that some pituitary cells express
CTLA-4, the receptor target of ipilimumab.9 Therefore, it
remains unclear whether the adverse effects are caused
by T-cells acting against antigens shared by tumor cells
and normal cells or from a direct antibody effect on
CTLA-4 receptors on pituitary cells, or both. Presenting
symptoms are related to a pituitary mass effect and
consequent hormone deficiencies.5,7,10 Clinical manifestations may be non-specific as they depend on the
extent of hormone deficiencies. Additionally, it is
often difficult to recognize many of these symptoms
in patients undergoing chemotherapy, but there should
be a low threshold to consider hypophysitis in a patient
taking ipilimumab. Typical symptoms include fatigue,
headache, and loss of libido. 10 Other symptoms
could include cold intolerance, visual disturbances,
hypotension, hypoglycemia and hyponatremia. Our
patient reported fatigue, but his diagnosis only became
apparent after hypotension was noted.
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MRI findings in ipilimumab-induced hypophysitis are
non-specific and are typically characterized by a diffuse
enlargement and homogeneous enhancement of
the pituitary gland. Less commonly, heterogeneous
enhancement has also been described.10-11 While it is
common to have radiographic evidence of hypopituitarism, a normal MRI is possible. Follow-up imaging
often shows resolution of abnormal findings after
hormone replacement.11
Pituitary hormone replacement with corticosteroids is
critical to treatment, assuming ACTH is low. Either high
dose or physiologic replacement dose corticosteroids
are needed. Current recommendations advocate for
high dose (1-2 mg/kg/day of prednisone or equivalent)
steroids for moderate to life threatening symptoms.12
However, it is not clear whether initial high doses of
corticosteroids are beneficial in treating hypophysitis.
While they may play a role in reducing inflammation, they
do not improve neuro-endocrine function compared
to physiologic doses. However, high doses of corticosteroids may increase morbidity through side effects.3, 13
Mineralocorticoid replacement is not needed since the
renin-angtiotensin-aldosterone system is still intact. It
should be at the discretion of the oncologist and endocrinologist as to whether ipilimumab should be continued
based on the condition of the patient and response
to hormone replacement. Hormone deficiencies can
improve, although corticotroph function seems to be
the least likely to recover.14 Many doctors recommend
close monitoring for hormone abnormalities in patients
receiving ipilimumab, especially after the third infusion.

Key Points
Hypophysitis is a well recognized side effect of
ipilimumab therapy. A high clinical suspicion for hypopituitarism in patients receiving the drug is imperative
due to the non-specific symptoms and potentially
life threatening consequences. Corticosteroids
should be promptly initiated as soon as secondary
adrenal insufficiency is detected. While ipilimumab
has many side effects, the drug has improved survival
in metastatic melanoma and remains an important
treatment option.
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